Skip to content

Efficacy evaluation and mechanism study of Jianpi Qushi Capsules on 2021 Delta variant strain of COVID-19 in Zhengzhou

Efficacy evaluation and mechanism study of Jianpi Qushi Capsules on 2021 Delta variant strain of COVID-19 in Zhengzhou

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055274
Enrollment
Unknown
Registered
2022-01-05
Start date
2021-08-26
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

case series:none

Sponsors

He'nan Provincial Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of He'nan University of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1. Meet the definition of a confirmed patient with new coronary pneumonia; 2. Aged 12-88 years; 3. The clinical classification of confirmed cases is light, common, severe, and critical; 4. Voluntarily accept the treatment and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Not using syndrome differentiation therapy or syndrome differentiation therapy for less than 3 days; 2. Dementia, various mentally ill patients; 3. Pregnant and lactating patients; 4. Those who are participating in clinical trials of other drugs and are known to be allergic to therapeutic drugs; 5. Patients with severe heart, brain, liver and kidney diseases.

Design outcomes

Primary

MeasureTime frame
Negative time for two consecutive throat swab nucleic acid tests;Blood routine;TCM syndrome score;

Countries

China

Contacts

Public ContactZhang Qinsheng

He'nan Provincial Hospital of Traditional Chinese Medicine

80792825@qq.com+86 13653711185

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026